Redrobe John P, Calo' Girolamo, Regoli Domenico, Quirion Rémi
Douglas Hospital Research Centre, McGill University, 6875 LaSalle Boulevard, Verdun, QC H4H 1R3, Canada.
Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):164-7. doi: 10.1007/s00210-001-0511-0. Epub 2001 Dec 20.
The present study investigated the effects of nociceptin, the peptide nociceptin receptor antagonist, [Nphe(1)]-nociceptin (1-13)-NH(2), and the non-peptide antagonist, J-113397, in the mouse forced swimming test, an animal model used for the screening of potential antidepressant drugs. Additional studies were performed with naloxone to exclude effects on traditional opioid receptors. Intracerebroventricular (ICV) administration of nociceptin (0.01-1 nmole) was devoid of any activity in the mouse forced swimming test, as was intraperitoneal (i.p.) administration of naloxone (1-10 mg/kg). ICV treatment with [Nphe(1)]-nociceptin (1-13)-NH(2) (25 nmole and 50 nmole) induced significant antidepressant-like activity ( P<0.01), as did administration of J-113397 (20 mg/kg, i.p; P<0.05). Open field analysis revealed that acute treatment with these molecules did not induce significant changes in locomotor activity at the doses tested. These results suggest that nociceptin, and its receptor, may play a role in depressive disorders and that the nociceptin system could represent a novel target for the development of new antidepressant drugs.
本研究在小鼠强迫游泳试验中,调查了痛敏肽、肽类痛敏肽受体拮抗剂[苯丙氨酸(1)]-痛敏肽(1 - 13)-NH₂以及非肽类拮抗剂J - 113397的作用,该试验是一种用于筛选潜在抗抑郁药物的动物模型。还使用纳洛酮进行了额外研究,以排除对传统阿片受体的影响。脑室内(ICV)注射痛敏肽(0.01 - 1纳摩尔)在小鼠强迫游泳试验中没有任何活性,腹腔注射(i.p.)纳洛酮(1 - 10毫克/千克)也是如此。脑室内注射[苯丙氨酸(1)]-痛敏肽(1 - 13)-NH₂(25纳摩尔和50纳摩尔)诱导出显著的抗抑郁样活性(P<0.01),腹腔注射J - 113397(20毫克/千克;P<0.05)也是如此。旷场分析显示,在测试剂量下,用这些分子进行急性治疗不会引起运动活动的显著变化。这些结果表明,痛敏肽及其受体可能在抑郁症中起作用,并且痛敏肽系统可能代表开发新型抗抑郁药物的一个新靶点。